Clinical trialPhase 1Recruiting
Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion
A Phase 1 Multiple Expansion Cohort Trial of MRTX1719 in Patients With Advanced Solid Tumors With Homozygous MTAP Deletion
- Outcome
- Ongoing
- Phase
- Phase 1
- Status
- Recruiting
- Study type
- Interventional
- Start
- 9 June 2022
- Expected end
- 10 December 2027
- Enrollment
- 336 participants
- Sites
- 25
- Primary outcomes
- Number of Patients who Experience Dose-Limiting Toxicity; Number of patients who experience a treatment-related adverse event; Objective response rate (ORR); Duration of response (DOR); Progression free survival (PFS)
- Sponsor
- Industry
- Results posted
- No
- Last update
- 2 September 2026
These are registry fields. A trial card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
Brief summary public domain (ClinicalTrials.gov)
This is a Phase 1, open-label, multicenter, study of the safety, tolerability, PK, PD, and anti-tumor activity of MRTX1719 patients with advanced, unresectable or metastatic solid tumor malignancy with homozygous deletion of the MTAP gene.
Detailed description public domain (ClinicalTrials.gov)
This first-in-human clinical trial will begin with an exploration of MRTX1719 dose and regimen. As potentially viable regimens are identified, Phase 1b expansion cohorts may be implemented to ensure sufficient safety experience, PK information, compare food effect and relative bioavailability between capsules and tablets, and early evidence of clinical activity are available.